The International Cancer Patient Coalition (ICPC) will host its landmark 2025 Working Meeting, From Global Declarations to Practical Delivery, on May 30–31 at Chicago’s Schreiber Center. This, invitation-only summit brings together global cancer leaders to confront the systemic gaps that prevent patients from accessing lifesaving precision oncology innovations.

Despite transformative tools like HER2-low therapies, ctDNA-guided trials, and radioligand theranostics, over half of eligible patients are still left behind due to diagnostic inconsistencies, reimbursement delays, and infrastructure barriers.

The Global Precision Gap: What’s at Stake

• 30–50% HER2-low diagnostic variability blocks access to antibody-drug conjugates (WHO 2024)
• 14-month delays in NSCLC resistance testing strand patients without next-line therapy (JCO Global Oncology 2025)
• 80% of hospitals lack MRD testing, despite 42% trial cost savings via decentralized models (Nature Medicine 2024)

From Policy Declarations to Practical Delivery

Across six action-driven sessions, attendees will co-design real-world strategies to:

• Standardize HER2-low testing through lab certification
• Eliminate NSCLC drug delays with pipeline reimbursement models
• Expand MRD access in LMICs via mobile units and outcomes-based pricing
• Scale radioligand therapy with new radiopharmacy hubs and regulatory reform

Please view full agenda here.

Global Experts Driving Change

The meeting brings together world-renowned experts whose work is shaping the future of precision oncology access:

Advancing Diagnostic Standards & Equity

• Dr. Hesham Elghazaly – Professor of Clinical Oncology, Ain Shams University (Egypt): Championing HER2-low testing standards in emerging health systems
• Dr. Janice Tsang – Consultant Oncologist, HKCTS & ESMO Faculty Member (Hong Kong): Driving diagnostic equity across Asia-Pacific cancer networks

Transforming Access Through Policy & Innovation

• Lee-Anne Zinetti – Executive Director, Global Oncology Portfolio Precision Medicine Strategy, Novartis (Switzerland): Shaping trial access through ctDNA integration and biomarker-driven strategies
• Luciana Holtz – Founder & President, Oncoguia (Brazil): Leading patient-centered reforms in access and reimbursement across Latin America

Scaling Theranostics & MRD Integration

• Dr. Ken Herrmann – Chair of Nuclear Medicine, Universitätsklinikum Essen (Germany): Setting infrastructure and regulatory benchmarks for radioligand therapy scale-up
• Dr. Vivek Subbiah – Chief, Early-Phase Drug Development, Sarah Cannon Research Institute (USA): Defining global MRD evidence frameworks for early detection and treatment optimization

Who Should Attend

• Policymakers shaping next-generation reimbursement frameworks
• Clinicians scaling tumour-agnostic and resistance-informed care
• Advocates prioritising rural and LMIC equity
• Industry leaders building sustainable innovation access pathways

Register Now: Seats are limited for this closed-door working meeting focused on transforming innovation into equitable care delivery. Please register here

About ICPC: The International Cancer Patient Coalition is a global alliance accelerating equitable access to cancer innovations. From synthetic data to screening equity, ICPC delivers policy action where patients need it most. (www.unite4cancer.com)

Source: ICPC